

ASCENSION

**CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SUPPLEMENTARY
INFORMATION (UNAUDITED)**

For the Three and Nine Months Ended March 31, 2026 and 2025

Ascension

Consolidated Financial Statements and Supplementary Information

For the Three and Nine Months Ended March 31, 2026 and 2025

Contents

Consolidated Financial Statements

Consolidated Balance Sheets	1
Consolidated Statements of Operations and Changes in Net Assets	3
Consolidated Statements of Cash Flows	5
Notes to Consolidated Financial Statements	7

Supplementary Information

Credit Group Financial Statements - Balance Sheet	50
Credit Group Financial Statements - Statement of Operations and Changes in Net Assets	52
Notes to Credit Group Financial Statements	54

Ascension

Consolidated Balance Sheets (unaudited) (Dollars in Thousands)

	March 31, 2026	June 30, 2025
Assets		
Current assets:		
Cash and cash equivalents	\$ 381,602	\$ 541,395
Short-term investments	41,294	43,974
Accounts receivable	3,015,652	3,031,345
Inventories	463,211	386,091
Due from counterparties <i>(see Notes 4 and 5)</i>	213,612	128,740
Estimated third-party payor settlements	536,490	212,757
Other	1,257,716	1,489,526
Total current assets	5,909,577	5,833,828
Long-term investments <i>(see Notes 4 and 5)</i>	23,385,701	19,449,512
Property and equipment, net	8,705,802	8,451,644
Other assets:		
Right-of-use assets - leases	954,704	925,440
Investment in unconsolidated entities	2,625,848	2,475,295
Intangible assets, net	1,746,156	1,578,191
Other	1,294,713	1,146,369
Total other assets	6,621,421	6,125,295
Total assets	\$ 44,622,501	\$ 39,860,279

Continued on next page.

Ascension

Consolidated Balance Sheets (unaudited) (Dollars in Thousands)

	March 31, 2026	June 30, 2025
Liabilities and net assets		
Current liabilities:		
Current portion of long-term debt	\$ 94,025	\$ 102,018
Long-term debt subject to short-term remarketing arrangements ¹	700,000	343,685
Short-term debt obligations	49,857	368,963
Current portion of lease obligations	192,106	190,964
Accounts payable and accrued liabilities	3,148,731	3,144,554
Estimated third-party payor settlements	405,566	439,062
Due to counterparties (see Notes 4 and 5)	862,001	756,642
Current portion of self-insurance liabilities	370,066	370,066
Other	511,352	540,392
Total current liabilities	6,333,704	6,256,346
Noncurrent liabilities:		
Long-term debt	9,029,186	5,243,897
Lease obligations, less current portion	805,441	775,563
Self-insurance liabilities	875,216	886,434
Pension and other postretirement liabilities	391,437	428,021
Other	1,325,039	1,337,042
Total noncurrent liabilities	12,426,319	8,670,957
Total liabilities	18,760,023	14,927,303
Net assets:		
Without donor restrictions:		
Controlling interest	22,229,409	21,457,262
Noncontrolling interests	2,983,877	2,846,009
Total net assets without donor restrictions	25,213,286	24,303,271
Net assets with donor restrictions	649,192	629,705
Total net assets	25,862,478	24,932,976
Total liabilities and net assets	\$ 44,622,501	\$ 39,860,279

¹ Consists of variable rate demand bonds with put options that may be exercised at the option of the bondholders, with stated repayment installments through 2065. In the event that bonds are not remarketed upon the exercise of put options for the variable bonds, management would utilize other sources to access the necessary liquidity. Potential sources include a drawdown on the System's lines of credit, issuing commercial paper, and liquidating investments.

The accompanying notes are an integral part of the consolidated financial statements.

Ascension

Consolidated Statements of Operations and Changes in Net Assets (unaudited) *(Dollars in Thousands)*

	The three months ended March 31,		The nine months ended March 31,	
	2026	2025	2026	2025
Operating revenue:				
Net patient service revenue	\$ 5,418,568	\$ 5,387,223	\$ 16,108,381	\$ 17,486,960
Other revenue	566,308	644,915	2,009,551	2,041,361
Total operating revenue	<u>5,984,876</u>	<u>6,032,138</u>	<u>18,117,932</u>	<u>19,528,321</u>
Operating expenses:				
Salaries and wages	2,294,607	2,408,688	6,954,638	7,765,424
Employee benefits	410,032	381,631	1,307,317	1,401,896
Purchased services	742,761	804,746	2,225,600	2,558,717
Professional fees	362,569	394,069	1,116,296	1,246,348
Supplies	833,299	824,162	2,508,015	2,727,871
Insurance	80,796	73,140	261,694	237,620
Interest	85,958	58,373	193,258	189,737
Provider tax	284,702	218,087	851,658	713,469
Depreciation and amortization	251,678	255,059	743,927	756,981
Other	699,542	696,662	2,179,756	2,361,891
Total operating expenses	<u>6,045,944</u>	<u>6,114,617</u>	<u>18,342,159</u>	<u>19,959,954</u>
Income (loss) from operations before self-insurance trust fund investment return, impairment and nonrecurring gains (losses), net	<u>(61,068)</u>	<u>(82,479)</u>	<u>(224,227)</u>	<u>(431,633)</u>
Self-insurance trust fund investment return	2,904	14,745	58,654	50,482
Income (loss) from recurring operations	<u>(58,164)</u>	<u>(67,734)</u>	<u>(165,573)</u>	<u>(381,151)</u>
Impairment and nonrecurring gains (losses), net	<u>(5,774)</u>	<u>(33,434)</u>	<u>(37,833)</u>	<u>(84,564)</u>
Income (loss) from operations	<u>(63,938)</u>	<u>(101,168)</u>	<u>(203,406)</u>	<u>(465,715)</u>
Nonoperating gains (losses):				
Investment return, net	85,483	151,621	1,066,628	910,026
Other	<u>(1,867)</u>	<u>(99,954)</u>	<u>(132)</u>	<u>(90,757)</u>
Total nonoperating gains (losses), net	<u>83,616</u>	<u>51,667</u>	<u>1,066,496</u>	<u>819,269</u>
Excess (deficit) of revenues and gains over expenses and losses	<u>19,678</u>	<u>(49,501)</u>	<u>863,090</u>	<u>353,554</u>
Less noncontrolling interests	<u>6,675</u>	<u>31,987</u>	<u>242,222</u>	<u>158,137</u>
Excess (deficit) of revenues and gains over expenses and losses attributable to controlling interest	<u>13,003</u>	<u>(81,488)</u>	<u>620,868</u>	<u>195,417</u>

Continued on next page.

Ascension

Consolidated Statements of Operations and Changes in Net Assets (unaudited) *(Dollars in Thousands)*

	The three months ended March 31,		The nine months ended March 31,	
	2026	2025	2026	2025
Net assets without donor restrictions, controlling interest:				
Excess (deficit) of revenues and gains over expenses and losses	\$ 13,003	\$ (81,488)	\$ 620,868	\$ 195,417
Net assets released from restrictions for property acquisitions	3,921	27,279	15,556	61,858
Change in pension liability	26,986	24,511	80,958	73,617
Change in unconsolidated entities' net assets	(1,280)	(16,494)	9,052	1,965
Other	17,328	24,260	45,710	11,209
Increase (decrease) in net assets without donor restrictions, controlling interest	<u>59,958</u>	<u>(21,932)</u>	<u>772,144</u>	<u>344,066</u>
Net assets without donor restrictions, noncontrolling interest:				
Excess (deficit) of revenues and gains over expenses and losses	6,675	31,987	242,222	158,137
Net contributions (distributions) of capital	(61,961)	(49,948)	(155,779)	(110,433)
Change in membership interest	1,334	13	50,147	1,923
Other	(50)	(22,347)	1,278	(25,489)
Increase (decrease) in net assets without donor restrictions, noncontrolling interest	<u>(54,002)</u>	<u>(40,295)</u>	<u>137,868</u>	<u>24,138</u>
Net assets with donor restrictions:				
Contributions and grants	22,818	30,187	71,313	83,960
Investment return	12,946	(71)	35,104	18,561
Net assets released from restrictions	(18,531)	(43,917)	(60,832)	(103,083)
Divestitures	-	-	(16,292)	(129,819)
Other	1,452	(12,103)	(9,803)	(3,530)
Increase (decrease) in net assets with donor restrictions	<u>18,685</u>	<u>(25,904)</u>	<u>19,490</u>	<u>(133,911)</u>
Increase (decrease) in net assets	24,641	(88,131)	929,502	234,293
Net assets, beginning of period	<u>25,837,837</u>	<u>24,145,461</u>	<u>24,932,976</u>	<u>23,823,037</u>
Net assets, end of period	<u>\$ 25,862,478</u>	<u>\$ 24,057,330</u>	<u>\$ 25,862,478</u>	<u>\$ 24,057,330</u>

The accompanying notes are an integral part of the consolidated financial statements.

Ascension

Consolidated Statements of Cash Flows (unaudited) (Dollars in Thousands)

	The nine months ended March 31,	
	2026	2025
Operating activities		
Increase (decrease) in net assets	\$ 929,502	\$ 234,293
Adjustments to reconcile increase (decrease) in net assets to net cash provided by operating activities:		
Depreciation and amortization	743,927	756,981
Amortization of bond premiums, discounts, and debt issuance costs	(17,677)	(16,673)
Loss (gain) on extinguishment of debt	(8,157)	(21,441)
Change in pension liability	(80,958)	(73,617)
Unrealized losses (gains) on investments without donor restrictions, net	(105,340)	219,195
Change in fair value of interest rate swaps	(23,057)	2,956
Change in equity of unconsolidated entities	(222,758)	(128,581)
Gain on sale of assets, net	(56,803)	(91,700)
Impairment and nonrecurring (gain) loss	5,332	25,014
Transfers to (from) sponsors, net	-	3,750
Donor restricted contributions, investment return and other	(61,140)	(61,296)
Distributions (contributions) of noncontrolling interest, net	155,779	110,433
Change in divested restricted net assets	16,292	129,819
Other	7,905	5,116
(Increase) decrease in:		
Short-term investments	2,680	9,871
Accounts receivable	19,285	679,895
Inventories and other current assets	28,454	(255,428)
Due from counterparties	(84,872)	48,120
Long-term investments	(3,150,391)	(853,510)
Intangible assets, net	(10,363)	(1,912)
Other assets	(134,125)	(79,891)
Increase (decrease) in:		
Accounts payable and accrued liabilities	888	(287,747)
Estimated third-party payor settlements, net	(357,065)	(187,068)
Due to counterparties	105,359	425,091
Advanced payments	-	(550,601)
Other current liabilities	14,041	149,798
Self-insurance liabilities	(11,218)	(100,714)
Other noncurrent liabilities	5,666	2,112
Net cash provided by (used in) operating activities	<u>(2,288,814)</u>	<u>92,265</u>

Continued on next page.

Ascension

Consolidated Statements of Cash Flows (unaudited) (Dollars in Thousands)

	The nine months ended March 31,	
	2026	2025
Investing activities		
Property, equipment, and capitalized software additions, net	\$ (1,119,399)	\$ (860,807)
Proceeds from sale of property and equipment	33,284	15,514
Distributions from (contributions to) unconsolidated entities, net	28,318	53,044
Net proceeds from (acquisition) divestiture of businesses	160,791	1,116,520
Net cash provided by (used in) investing activities	(897,006)	324,271
Financing activities		
Issuance of short-term debt obligations	873,063	4,226,405
Repayment of short-term debt obligations	(1,192,170)	(4,131,222)
Issuance of long-term debt	4,738,296	18,270
Repayment of long-term debt, including financing lease obligations	(584,055)	(614,799)
Decrease (increase) in assets under bond agreements	(704,564)	(7)
Transfers (to) from sponsors, net	-	(3,750)
Donor restricted contributions, investment return, and other	61,140	61,296
(Distributions) contributions of noncontrolling interest, net	(155,779)	(110,433)
Net cash provided by (used in) financing activities	3,035,931	(554,240)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(149,889)	(137,704)
Cash, cash equivalents, and restricted cash at beginning of period	577,377	714,794
Cash, cash equivalents, and restricted cash at end of period	\$ 427,488	\$ 577,090
Cash and cash equivalents	\$ 381,602	\$ 527,558
Restricted cash, included in long-term investments	45,886	49,532
Cash, cash equivalents, and restricted cash at end of period	\$ 427,488	\$ 577,090

The accompanying notes are an integral part of the consolidated financial statements.

Ascension

Notes to Consolidated Financial Statements (unaudited) (Dollars in Thousands)

1. Organization and Mission

Organizational Structure

Ascension Health Alliance, d/b/a Ascension (Ascension), is a Missouri nonprofit corporation formed on September 13, 2011. Ascension is a Catholic national health system consisting primarily of nonprofit corporations that own and operate local healthcare facilities, or Ministry Markets, located in 16 states and the District of Columbia. Ascension also serves as the direct or indirect member or shareholder of various subsidiaries including, but not limited to:

- Ascension Healthcare
- Ascension Capital
 - o Ascension Investment Management (AIM)
 - o Ascension Ventures (AV)
 - o AV Holding Company
- Ascension Care Management
- Ascension Foundation
- Ascension Holdings
- Ascension Leadership Academy
- Ascension Risk Services
- Ascension Technologies
- SmartHealth Solutions
- The Resource Group

Ascension is also the majority investor in Ascension Alpha Fund, LLC (Alpha Fund), a limited liability company organized in the state of Delaware, as well as the majority limited partner of various venture capital funds (the Venture Funds), as further discussed in the Investment Funds note. The Alpha Fund and the Venture Funds are collectively referred to as Investment Funds. Ascension and its member organizations are hereafter referred to collectively as the System.

Sponsorship

Ascension is sponsored by the Ascension Sponsor, a Public Juridic Person. The Participating Entities of the Ascension Sponsor include the Daughters of Charity of St. Vincent de Paul, St. Louise Province; the Congregation of St. Joseph; the Congregation of the Sisters of St. Joseph of Carondelet; the Congregation of Alexian Brothers of the Immaculate Conception Province, Inc. – American Province; and the Sisters of the Sorrowful Mother of the Third Order of St. Francis of Assisi – US/Caribbean Province.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

1. Organization and Mission (continued)

Mission

The System directs its governance and management activities toward strong, vibrant, Catholic Ministries united in service and healing, and dedicates its resources to spiritually centered care which sustains and improves the health of the individuals and communities it serves. In accordance with the System's mission of service to those persons living in poverty and other vulnerable persons, each Ministry Market accepts patients regardless of their ability to pay. The System uses the following categories to report the costs of community benefit provided:

- Traditional charity care includes the cost of services provided to persons who cannot afford healthcare because of inadequate resources, including those who are uninsured or underinsured.
- Unpaid cost of public programs, excluding Medicare, represents the unpaid cost of services provided to persons covered by public programs for persons living in poverty and other vulnerable persons.
- Unreimbursed costs of programs for persons living in poverty and other persons who are vulnerable, and programs for the broader community, including health promotion and education, health clinics and screenings, and medical research.
- Unpaid costs of Medicare represents the unpaid cost of services provided to Medicare recipients.

Discounts are provided to all uninsured and underinsured patients, including those with the means to pay. Discounts provided to patients who did not qualify for financial assistance are not included in the cost of providing care for persons living in poverty and other community benefit programs. Traditional charity care and the unpaid cost of public programs are calculated based on a cost to charge ratio methodology.

The cost of traditional charity care provided was \$355,932 and \$407,501 for the nine months ended March 31, 2026 and 2025, respectively. See Community Benefit note for further information related to Ascension's cost of other community benefit.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) *(Dollars in Thousands)*

2. Significant Accounting Policies

Principles of Consolidation

The System consolidates all entities for which operating control is exercised by the System or one of its member entities, and all significant inter-entity transactions have been eliminated in consolidation.

Use of Estimates

Management has made estimates and assumptions that affect the reported amounts of certain assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

Fair Value of Financial Instruments

Carrying values of financial instruments classified as current assets and current liabilities approximate fair value. The fair values of financial instruments measured at fair value are disclosed in the Fair Value Measurements note.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and interest-bearing deposits with original maturities of three months or less.

Short-Term Investments

Short-term investments consist of investments with original maturities exceeding three months and up to one year.

Inventories

Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or market value using first-in, first-out (FIFO) or a methodology that closely approximates FIFO.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Long-Term Investments and Investment Return

Long-term investments are primarily comprised of the Investment Funds, which are consolidated by the System. The System's investments, including the Investment Funds, are measured at fair value or net asset value. Further information about long-term investments and investment return is discussed in the Investment Funds, Cash and Investments, and Fair Value Measurements notes.

Long-term investments include assets limited as to use of \$2,417,482 and \$1,448,748 at March 31, 2026 and June 30, 2025, respectively. Assets limited as to use are primarily investments with donor restrictions, including restricted cash and cash equivalents, assets under bond agreement, and assets placed in trust or held by captive insurance companies for the payment of self-insured claims.

Purchases and sales of investments are accounted for on a trade-date basis. The cost of substantially all securities sold is based on the FIFO method. Investment returns consist of dividends, interest, and realized and unrealized gains and losses. Investment returns, excluding returns of self-insurance trust funds and restricted investment returns, are reported as Nonoperating gains (losses) in the Consolidated Statements of Operations and Changes in Net Assets. Investment returns of Self-insurance trust funds are reported as a separate component of income from operations in the Consolidated Statements of Operations and Changes in Net Assets.

Property and Equipment

Property and equipment are stated at cost or, if donated, at fair market value at the date of the gift. Depreciation is determined on a straight-line basis over the estimated useful lives of the related assets. The range of estimated useful lives used in computing depreciation is as follows: buildings and leasehold improvements, primarily 2 to 40 years; and equipment, primarily 2 to 20 years. Depreciation expense for both the three months ended March 31, 2026 and 2025 was approximately \$203,000. Depreciation expense for the nine months ended March 31, 2026 and 2025 was approximately \$597,000 and \$607,000, respectively.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

A summary of property and equipment in the Consolidated Balance Sheets, is as follows:

	March 31, 2026	June 30, 2025
Land and improvements	\$ 1,084,862	\$ 1,100,920
Buildings and equipment	16,676,389	16,024,384
	17,761,251	17,125,304
Less accumulated depreciation	9,924,857	9,574,459
	7,836,394	7,550,845
Construction in progress	869,408	900,799
Total property and equipment, net	\$ 8,705,802	\$ 8,451,644

Several capital projects have remaining construction and related equipment purchase commitments of approximately \$800,000 as of March 31, 2026.

Investment in Unconsolidated Entities

Investments in entities where the System does not have operating control but has the ability to exercise significant influence are primarily recorded under the equity method of accounting and included in Investment in unconsolidated entities on the System's Consolidated Balance Sheets, and results of operations are included in Other revenue in the Consolidated Statements of Operations and Changes in Net Assets.

Ascension's noncontrolling interest in Henry Ford Health System (HFHS) (see Organizational Changes note) is an equity method investment, included in Investment in unconsolidated entities in the Consolidated Balance Sheets, where the fair value option is elected based on the nature of the investment. The fair value of this Level 3 investment (see Level 3 definition in the Fair Value Measurements note) is estimated based on a combination of the income and market approaches. The income approach considers the projected operating performance of the company and discounts future economic benefits back to present value using a risk adjusted rate of return, while the market approach considers prior company and other comparable transactions, and public guideline company information. Changes in the fair value of this investment are included in Other revenue in the Consolidated Statement of Operations and Changes in Net Assets.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

As of March 31, 2026 and June 30, 2025, Ascension's investment in HFHS is approximately \$1,300,000.

Intangible Assets, net

Intangible assets, net primarily consist of goodwill and capitalized computer software costs, including internally developed software. Costs incurred in the development and installation of internal use software are capitalized subsequent to project approval, for projects whose completion is probable. A summary of intangible assets, net, as presented in the Consolidated Balance Sheets, is as follows:

	March 31, 2026	June 30, 2025
Capitalized software costs	\$ 2,497,607	\$ 2,541,384
Software in progress	274,601	129,473
Less accumulated amortization	2,065,497	2,067,911
Capitalized software costs, net	706,711	602,946
Goodwill	981,093	920,193
Other, net	58,352	55,052
Total intangible assets, net	\$ 1,746,156	\$ 1,578,191

Goodwill and other intangible assets whose lives are indefinite are not amortized and are evaluated for impairment at a reporting unit level at least annually, or when circumstances indicate a possible impairment may exist. This evaluation is based on a qualitative assessment that considers factors such as the reporting unit fair value and carrying value, industry considerations and performance outlook. If the qualitative assessment indicates it is more likely than not that goodwill is impaired, a quantitative assessment is performed.

Capitalized computer software and other intangible assets with definite lives are amortized on a straight-line basis over their expected useful lives of primarily 3 to 7 years for capitalized software and primarily 5 to 30 years for other intangible assets with definite lives.

Amortization expense for these intangible assets for the three months ended March 31, 2026 and 2025 was approximately \$49,000 and \$52,000, respectively.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Amortization expense for these intangible assets for the nine months ended March 31, 2026 and 2025 was approximately \$147,000 and \$150,000, respectively.

Noncontrolling Interests

The Consolidated Financial Statements include all assets, liabilities, revenues, and expenses of entities that are controlled and consolidated by the System. Noncontrolling interests in the Consolidated Financial Statements represent the portion of Net assets and Excess (deficit) of revenues and gains over expenses and losses attributable to entities outside the System, for those controlled and consolidated entities in which the System's ownership interest is less than 100%.

Net Assets

Net Assets Without Donor Restrictions

Net assets without donor restrictions are those whose use by the System has not been limited by donors and are available for general operating use.

Net Assets With Donor Restrictions

Net assets with donor restrictions include those whose use by the System has been limited by donors for a specific time period or purpose, primarily for patient care, operations, and property and equipment.

This category also includes net assets restricted by donors to be maintained in perpetuity. The income generated from these restricted investments is primarily used to purchase equipment and to provide charity care and other health and educational services. Contributions with donor-imposed restrictions that are met in the same reporting period are reported as net assets without donor restrictions.

Performance Indicator

The performance indicator is the Excess (deficit) of revenues and gains over expenses and losses. Net assets released from restrictions for property acquisitions, Change in pension liability, and Change in unconsolidated entities' net assets are not included in the performance indicator.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Operating and Nonoperating Activities

The System's primary mission is to meet the healthcare needs in its communities served through a broad range of general and specialized healthcare services, including inpatient acute care, outpatient services, long-term care, and other healthcare services. Activities directly associated with the furtherance of this purpose are classified as operating activities, while activities resulting in gains or losses peripheral to the System's primary mission are classified as nonoperating.

Net Patient Service Revenue and Accounts Receivable

Net patient service revenue relates to contracts with patients, and in most cases involve a third-party payor (Medicare, Medicaid, commercial and other managed care insurance companies) in which the System's performance obligations are to provide healthcare services. Net patient service revenues are recorded at expected collectible amounts over the time in which obligations to provide healthcare services are satisfied. Revenue is accrued to estimate the amount of revenue earned to date for patients who have not been discharged and whose care services are not complete as of the reporting period. Substantially all the System's performance obligations are satisfied in one year.

The transaction price is determined based on gross charges for services provided, reduced by contractual adjustments provided to third-party payers, discounts provided to uninsured patients in accordance with the System's charity care policy, and implicit price concessions provided primarily to uninsured patients. Patients who have healthcare insurance may also have discounts applied related to their copayment or deductible. Implicit price concessions are recorded as a direct reduction to net patient service revenue and are based primarily on historical collection experience.

Estimates of contractual adjustments and discounts are determined by major payor classes for inpatient and outpatient revenues based on contractual agreements, discount policies and historical experience. Management regularly reviews the contractual estimation process to consider and incorporate updates to laws and regulations and frequent changes in commercial and managed care contractual terms resulting from contract renegotiations and renewals.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Adjustments to revenue from Medicare, Medicaid and other third-party payers related to prior periods increased net patient service revenue by \$312,746 and \$124,792 for the nine months ended March 31, 2026 and 2025, respectively.

Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. Such estimates are determined through either a probability-weighted estimate or an estimate of the most likely amount, depending on the circumstances related to a given estimated settlement item.

These settlements are estimated based on the terms of the payment agreement with the payer, correspondence from the payer and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews and investigations.

Net patient service revenue earned for the three months ended March 31, 2026 and 2025, is as follows:

	The three months ended March 31,	
	2026	2025
Inpatient care	\$ 2,529,227	\$ 2,579,336
Ambulatory care	2,310,877	2,193,384
Physician practices	495,490	511,754
Long-term care	82,974	102,749
Total net patient service revenue	\$ 5,418,568	\$ 5,387,223

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Net patient service revenue earned for the nine months ended March 31, 2026 and 2025, is as follows:

	The nine months ended March 31,	
	2026	2025
Inpatient care	\$ 7,579,504	\$ 8,235,135
Ambulatory care	6,766,719	7,134,425
Physician practices	1,505,993	1,791,785
Long-term care	256,165	325,615
Total net patient service revenue	<u>\$ 16,108,381</u>	<u>\$ 17,486,960</u>

The System grants credit without collateral to its patients. Net patient service revenues earned by payor and significant concentrations of accounts receivable are as follows:

	Net Patient Service Revenue		Accounts Receivable	
	The nine months ended		March 31,	June 30,
	2026	2025	2026	2025
Medicare - traditional and managed	33.2 %	35.7 %	27.2 %	27.0 %
Medicaid - traditional and managed	14.9	15.9	9.4	9.2
Other commercial and managed care	44.9	44.7	46.5	47.8
Self-Pay and other	7.0	3.7	16.9	16.0
	<u>100.0 %</u>	<u>100.0 %</u>	<u>100.0 %</u>	<u>100.0 %</u>

Deductibles, copayments, and coinsurance under third-party payment programs which are the patient's responsibility are included within the primary payor category in the preceding table.

The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient deductibles and copayments remain outstanding. Accounts are written off when all reasonable internal and external collection efforts have been performed.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) *(Dollars in Thousands)*

2. Significant Accounting Policies (continued)

Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. The estimates for implicit price concessions are based upon management's assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer healthcare coverage and other collection indicators.

Management relies on the results of detailed reviews of historical write-offs and collections of revenues and accounts receivable as a primary source of information in estimating the collectability of accounts receivable. Management updates the hindsight analysis during the year, using collection history and write-off data. The results of these updates have not resulted in material adjustments to the valuations of accounts receivable or period-to-period comparisons of results of operations.

Other Revenue

Other revenues primarily relate to amounts recognized for providing goods and services not directly associated with patient care, over the period of time the performance obligations are satisfied. Amounts recognized reflect consideration due from customers, third party payors, and others. Components of Other revenue are included in the following tables for the three and nine months ended March 31, 2026 and 2025, respectively:

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued)
(Dollars in Thousands)

2. Significant Accounting Policies (continued)

	The three months ended March 31,	
	2026	2025
Cafeteria and vending	\$ 14,541	\$ 16,659
Contracted services	166,415	160,283
Donations and grants	41,209	97,012
Gains on asset sales	1,563	2,674
Insurance plans	46,318	44,326
Income from investment in unconsolidated entities	44,107	32,563
Lease and rental income	18,834	18,011
Retail pharmacy	201,534	221,466
Value based programs	9,411	7,952
Other	22,376	43,969
Total other revenue	<u>\$ 566,308</u>	<u>\$ 644,915</u>

	The nine months ended March 31,	
	2026	2025
Cafeteria and vending	\$ 45,589	\$ 53,936
Contracted services	513,523	392,141
Donations and grants	144,211	196,708
Gains on asset sales	58,310	100,035
Insurance plans	160,825	206,519
Income from investment in unconsolidated entities	215,788	116,671
Lease and rental income	53,365	59,809
Retail pharmacy	656,588	661,143
Value based programs	84,349	109,602
Other	77,003	144,797
Total other revenue	<u>\$ 2,009,551</u>	<u>\$ 2,041,361</u>

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Impairment and Nonrecurring Gains (Losses), Net

Long-lived assets are reviewed for impairment whenever events or business conditions indicate the carrying amount of such assets may not be fully recoverable. Initial assessments of recoverability are based on estimates of undiscounted future net cash flows associated with an asset or group of assets. Where impairment is indicated, the carrying amount of an asset or group of assets is reduced to fair value based on income and market approaches, which may include discounted estimates of future net cash flows, market comparables for similar assets, and appraisals.

Nonrecurring gains (losses) primarily include losses associated with the recognition of assets and liabilities held for sale and assets sold, and also include natural disaster losses and related insurance proceeds.

Amortization

Bond issuance costs, discounts, and premiums are amortized over the term of the bonds or the fixed interest period, if applicable, primarily using a method approximating the effective interest method.

Income Taxes

The System's tax-exempt organizations are described under Internal Revenue Code Section 501(c)(3), and their related income is exempt from federal income tax under Section 501(a). The System accounts for uncertainty in income tax positions by applying a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The System has determined that no material unrecognized tax benefits or liabilities exist as of March 31, 2026.

Contingencies

Regulatory and legal contingencies are evaluated for risk of loss, and accruals are made when such losses are deemed probable and can be reasonably estimated. Liabilities accrued for professional liability claims include amounts covered by excess insurance, and as such, the Company records a receivable for the expected reimbursement of losses covered by excess insurance at the time liabilities are accrued.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

2. Significant Accounting Policies (continued)

Reclassifications

Certain reclassifications were made to prior periods' Consolidated Financial Statements to conform to the March 31, 2026 presentation.

New Accounting Standards Adopted

The Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2025-06, *Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40)* in September 2025, which guidance revises the criteria for capitalization of internal use software development costs. Ascension adopted this guidance effective July 1, 2025, with no material impact to the Consolidated Financial Statements.

Subsequent Events

The System evaluates the impact of subsequent events, which are events that occur after the Consolidated Balance Sheet date, but before the Consolidated Financial Statements are issued, for potential recognition or disclosure in the Consolidated Financial Statements as of the Consolidated Balance Sheet date. For the nine months ended March 31, 2026, the System evaluated subsequent events through May 15, 2026, representing the issuance date of the Consolidated Financial Statements.

3. Organizational Changes

Business Combinations

Cedar Park Regional Medical Center

On June 30, 2025, Ascension Texas and Ascension Seton (collectively Ascension Texas) completed the transaction to acquire the remaining equity interest in Cedar Park Regional Medical Center, including interests in certain related joint ventures. Fair values of net assets acquired will be finalized by the end of the measurement period on June 30, 2026.

AMSURG

In June 2025, Ascension entered into a definitive agreement to acquire AMSURG, an ambulatory surgery development, management, and operations services company. This transaction is expected to be finalized after all necessary approvals are obtained.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

3. Organizational Changes (continued)

Divestitures

Assets and liabilities held for sale were approximately \$145,000 and \$44,000, respectively, at June 30, 2025, included in Other current assets and Other current liabilities, respectively, in the Consolidated Balance Sheet at that date. These amounts are primarily associated with the transactions discussed below. In addition, Long Term Investments in the Consolidated Balance Sheet of approximately \$28,000 at June 30, 2025 were contributed with the July 1, 2025 divestiture in Michigan.

Losses associated with certain transactions below are included in Impairment and nonrecurring gains (losses), net in the Consolidated Statement of Operations for the three and nine months ended March 31, 2026 and 2025.

During the nine months ended March 31, 2026 and the year ended June 30, 2025, Ascension Senior Living completed the sale of certain assets and primarily all operations of six senior living facilities to various purchasers.

On July 1, 2025, Ascension Healthcare and Ascension Michigan Home Office completed the membership substitution of four hospitals and certain related assets and operations in southwestern Michigan to Beacon Health System.

On March 1, 2025, Presence Care Transformation Corporation (Presence), a wholly owned subsidiary of Ascension Healthcare, sold substantially all assets and operations, as well as related clinical and other businesses, of nine hospitals and four senior living facilities in the greater Chicago, Illinois area to Prime Healthcare Services, Inc.

On November 1, 2024, Ascension Healthcare transitioned its membership interest in the St. Vincent's Health System in Alabama to UAB Health System Authority.

On October 1, 2024, Ascension Healthcare and Ascension Michigan, a wholly owned subsidiary of Ascension Healthcare, contributed its membership interest in southeast and mid Michigan hospitals and related ancillary entities to HFHS, and obtained a 20% noncontrolling interest in HFHS.

On August 1, 2024, Ascension Healthcare completed the membership substitution of its northern Michigan hospitals and related ancillary entities to MyMichigan Health.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) *(Dollars in Thousands)*

4. Investment Funds

A significant portion of Ascension's investments are held within the Investment Funds. Certain system entities hold additional investments outside of the Investment Funds.

Alpha Fund

The Alpha Fund is consolidated by the System and includes the investment interests of the System and noncontrolling Alpha Fund investors.

AIM, a wholly owned subsidiary of the System, serves as the manager and primary investment advisor of the Alpha Fund, overseeing the investment strategies offered to the Alpha Fund's investors. AIM provides expertise in the areas of asset allocation, selection and monitoring of outside investment managers, and risk management.

Ascension and the Alpha Fund invest in certain alternative investment funds, which include contractual commitments to provide capital contributions during investment periods, which are typically five years, and can extend to the end of the fund term. As of March 31, 2026, unfunded capital commitments were approximately \$1,075,000, of which approximately \$209,000 were attributable to Alpha Fund investors other than Ascension. Funding under these commitments, if required, is expected to be primarily satisfied by the liquidation of existing investments in the Alpha Fund.

In the normal course of business, the Alpha Fund enters into derivative contracts (derivatives) for trading purposes, as well as repurchase agreements, within approved guidelines. Advisors selected by AIM to manage the Alpha Fund's assets may actively trade futures contracts, options, swaps, forward settling mortgage-backed securities, index-based instruments, and foreign currency forward contracts. AIM may also direct these advisors to execute derivative transactions. These transactions are used to hedge against changes in interest rates, security prices, currency fluctuations, and other market developments to manage risk or for the purposes of earning additional income.

Derivatives are either exchange-traded or over the counter contracts. Exchange-traded derivatives are standard contracts traded on a regulated exchange. Over the counter contracts are private contracts negotiated with counterparties. At March 31, 2026 and June 30, 2025, the gross notional value of Alpha Fund derivatives outstanding was approximately \$5,026,000 and \$3,981,000, respectively. See the Fair Value Measurements note for discussion of the Alpha Fund derivatives' fair value determination.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

4. Investment Funds (continued)

At March 31, 2026 and June 30, 2025, the fair value of Alpha Fund derivatives in an asset position was \$121,155 and \$83,226, respectively, while the fair value of Alpha Fund derivatives in a liability position was \$85,344 and \$80,549 at March 31, 2026 and June 30, 2025, respectively. These derivatives are included in Long-term investments in the Consolidated Balance Sheets.

The Alpha Fund is a party to repurchase agreements, whereby certain securities of the Alpha Fund's investments are sold to a counterparty in return for cash as collateral for the purchased securities, on a short-term basis. The fair value of investments under repurchase agreements at March 31, 2026 and June 30, 2025 was approximately \$669,000 and \$688,000, respectively. As of March 31, 2026 and June 30, 2025, cash collateral received and invested within the Alpha Fund was approximately \$659,000 and \$678,000, respectively. This collateral is included in Long-term investments, with an offsetting liability within Due to counterparties, on the Consolidated Balance Sheets.

The Alpha Fund participates in a securities lending program, whereby a portion of the Alpha Fund's investments are loaned to selected brokerage firms in return for cash and/or securities from the brokers as collateral for the investments loaned, usually on a short-term basis. Collateral provided by brokers is maintained at levels approximating 102% of the fair value of the securities on loan, and is adjusted daily for market fluctuations. At March 31, 2026 and June 30, 2025, the fair value of collateral, comprised primarily of non-cash collateral, was approximately \$587,000 and \$486,000, respectively. Cash collateral is recorded in Other current assets, with corresponding liabilities in Other current liabilities, in the Consolidated Balance Sheets at those dates. In the event of nonperformance by the counterparties to the securities lending agreements, the Alpha Fund could be exposed to loss.

Due from counterparties and Due to counterparties in the Consolidated Balance Sheets represent the Alpha Fund's positions and amounts due from or to various brokers, primarily for security transactions not yet settled, as well as amounts due to or from other counterparties for repurchase agreements.

Venture Funds

The Venture Funds are consolidated by the System and include the investment interests of the System and other noncontrolling limited partners. The general partners of the Venture Funds are wholly owned subsidiaries of AV Holding Company. The Venture Funds invest primarily in equity and convertible debt securities of privately held domestic entities, and are reported at fair value.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

5. Cash and Investments

The System's cash and investments are reported in the Consolidated Balance Sheets as presented in the table that follows. Total cash and investments, net, includes the net assets of Investment Funds. The Investment Funds' other assets (liabilities), net are primarily amounts due from and (to) counterparties. System unrestricted cash and investments, net, represent the System's cash and investments excluding assets limited as to use and the noncontrolling interests of Investment Funds.

	March 31, 2026	June 30, 2025
Cash and cash equivalents	\$ 381,602	\$ 541,395
Short-term investments	41,294	43,974
Long-term investments	23,385,701	19,449,512
Subtotal	23,808,597	20,034,881
Investment Funds' other assets (liabilities), net	(617,990)	(597,482)
Total cash and investments, net	23,190,607	19,437,399
Less noncontrolling interest of Investment Funds	2,572,602	2,509,316
System cash and investments, including assets limited as to use	20,618,005	16,928,083
Less assets limited as to use:		
Under bond agreement ¹	704,701	137
Self-insurance trust funds	1,098,085	854,723
With donor restrictions	614,696	593,888
Total assets limited as to use	2,417,482	1,448,748
System unrestricted cash and investments, net	\$ 18,200,523	\$ 15,479,335

¹Primarily relates to bond proceeds held in escrow. See Debt note.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

5. Cash and Investments (continued)

The System's composition of cash and cash equivalents, short-term investments and long-term investments, which include certain assets limited as to use, is summarized as follows:

	March 31, 2026	June 30, 2025
Cash and cash equivalents and short-term investments	\$ 650,101	\$ 661,170
Pooled short-term investment fund	1,577,337	940,858
U.S. government, state, municipal and agency obligations	5,039,692	1,943,706
Corporate and foreign fixed income securities	975,364	921,116
Asset-backed securities	1,425,557	1,187,541
Equity securities	7,042,932	7,226,649
Alternative investments and other investments:		
Private equity and real estate funds	5,041,245	5,005,763
Private credit and energy funds	1,020,213	1,175,108
Hedge funds	550,498	523,261
Other investments	485,658	449,709
Total alternative investments and other investments	7,097,614	7,153,841
Total cash and cash equivalents, short-term investments, and long-term investments	\$ 23,808,597	\$ 20,034,881

Total investment return includes the System's return on Investment Funds and on certain investments held and managed outside the Investment Funds. System investment return is net of the investment return earned by the noncontrolling interests of the Investment Funds.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

5. Cash and Investments (continued)

Investment return recognized by the System for the three months ended March 31, 2026 and 2025, is summarized as follows:

	The three months ended	
	March 31,	
	2026	2025
Interest and dividends	\$ 152,803	\$ 117,053
Net gains (losses) on investments reported at fair value	(64,416)	49,312
Restricted investment return and unrealized gains (losses), net	12,946	(71)
Total investment return, net	101,333	166,294
Less Investment Funds' noncontrolling interest return, net	(29,987)	2,733
System investment return, net	\$ 131,320	\$ 163,561

Investment return recognized by the System for the nine months ended March 31, 2026 and 2025, is summarized as follows:

	The nine months ended	
	March 31,	
	2026	2025
Interest and dividends	\$ 329,183	\$ 302,721
Net gains (losses) on investments reported at fair value	796,099	657,787
Restricted investment return and unrealized gains (losses), net	35,104	18,561
Total investment return, net	1,160,386	979,069
Less Investment Funds' noncontrolling interest return, net	120,246	67,375
System investment return, net	\$ 1,040,140	\$ 911,694

Total and system investment returns are net of external and direct internal investment expenses.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

6. Financial Assets and Liquidity Resources

As of March 31, 2026 and June 30, 2025, financial assets and liquidity resources available within one year for expenditures, such as operating expenses, principal payments on debt, and capital expenditures, are as follows:

	March 31, 2026	June 30, 2025
Financial assets:		
Cash and cash equivalents	\$ 381,602	\$ 541,395
Short-term investments	41,294	43,974
Accounts receivable	3,015,652	3,031,345
Due from counterparties	213,612	128,740
Other current assets ¹	1,257,716	1,445,849
Long term investments ²	23,385,701	19,449,512
Total financial assets	28,295,577	24,640,815
Less:		
Assets limited as to use and internally designated funds	2,545,964	1,541,924
Noncontrolling interests of Investment Funds	2,572,602	2,509,316
Investments with liquidity more than one year	5,277,062	5,354,776
Total financial assets available within one year	17,899,949	15,234,799
Liquidity resources:		
Unused line(s) of credit	1,500,000	1,500,000
Total financial assets and liquidity resources available within one year	\$ 19,399,949	\$ 16,734,799

¹ Includes assets held for sale, net of liabilities held for sale, of approximately \$23,000 at March 31, 2026 and \$101,000 at June 30, 2025.

² Long-term investments of approximately \$28,000 at June 30, 2025 were contributed upon the close of the July 1, 2025 Michigan transaction discussed in the Organizational Changes note.

As part of the System's investment policy, highly liquid investments are held to enhance the ability to satisfy liquidity requirements.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements

The System measures the fair value of assets and liabilities in accordance with FASB ASC 820, *Fair Value Measurement*. Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability at the measurement date. Assets and liabilities reported at fair value are classified and disclosed in one of the following four categories:

Level 1 – Quoted prices (unadjusted) that are readily available in active markets/exchanges for identical assets or liabilities.

Level 2 – Pricing inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 pricing inputs include prices quoted for similar assets and liabilities in active markets/exchanges or prices quoted for identical or similar assets and liabilities in markets that are not active. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 – Significant pricing inputs that are unobservable for the asset or liability, including assets or liabilities for which there is little, if any, market activity for such asset or liability. Inputs to determine the fair value of Level 3 assets and liabilities require management judgment and estimation.

Net Asset Value – Values are based on the calculated net asset value. The calculated net asset values for underlying investments are fair value estimates determined by an external fund manager and other sources based on quoted market prices, operating results, balance sheet stability, growth, and other business and market sector factors.

The System categorizes, for disclosure purposes, assets and liabilities measured at fair value in the Consolidated Financial Statements based upon whether the inputs used to determine their fair values are observable or unobservable. Observable inputs are inputs that are based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about pricing the asset or liability based on the best information available in the circumstances.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an asset's or liability's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement of the asset or liability.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

The System's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

As of March 31, 2026 and June 30, 2025, the assets and liabilities listed in the fair value hierarchy tables below use the following valuation techniques and inputs:

Cash Equivalents and Short-Term Investments

Cash equivalents and certain short-term investments include certificates of deposit, whose fair value is based on cost plus accrued interest. Significant observable inputs include security cost, maturity, and relevant short-term interest rates.

Other short-term investments designated as Level 2 investments primarily consist of commercial paper, whose fair value is based on the income approach. Significant observable inputs include security cost, maturity, credit rating, interest rate, and par value.

Pooled Short-Term Investment Fund

The pooled short-term investment fund is a short-term exchange traded money market fund primarily invested in treasury securities.

U. S. Government, State, Municipal, and Agency Obligations

The fair value of investments in U.S. government, state, municipal, and agency obligations is primarily determined using techniques consistent with the income approach. Significant observable inputs include benchmark yields, reported trades, observable broker/dealer quotes, and issuer spreads.

Corporate and Foreign Fixed Income Securities

The fair value of investments in U.S. and international corporate bonds and foreign government bonds is primarily determined using techniques that are consistent with the market approach. Significant observable inputs include benchmark yields, reported trades, observable broker/dealer quotes, issuer spreads, and security-specific characteristics (e.g., such as early redemption options).

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

Asset-backed Securities

The fair value of U.S. agency, mortgage, and other asset-backed securities is primarily determined using techniques that are consistent with the income approach. Significant observable inputs include prepayment speeds and spreads, benchmark yield curves, volatility measures, and observable broker/dealer quotes.

Equity Securities

The fair value of investments in U.S. and international equity securities is primarily determined using techniques that are consistent with the market and income approaches. The values for underlying investments are based on readily available quoted market prices or represent fair value estimates based on market prices, operating results, balance sheet stability, growth, dividend, dividend yield, and other business and market sector fundamentals.

Alternative Investments and Other Investments

Alternative investments consist of private equity and other investments. The fair value of private equity is primarily determined using techniques consistent with both the market and income approaches, based on the System's estimates and assumptions in the absence of observable market data. The market approach considers comparable company, comparable transaction, and company-specific information, including but not limited to restrictions on disposition, subsequent purchases of the same or similar securities by other investors, pending mergers or acquisitions, and current financial position and operating results. The income approach considers the projected operating performance of the portfolio company. Other investments primarily include derivative assets and derivative liabilities of the Alpha Fund, including level 1 exchange traded derivatives. Fair values of other derivatives are primarily determined using techniques consistent with the market approach.

Significant observable inputs to valuation models include the time value of money, counterparty credit risk, interest rates, Treasury yields, volatilities, credit spreads, maturity date, recovery rates, and the current market and contractual prices of the underlying financial instruments.

The fair value of hedge funds, private equity funds, private credit and energy funds, and real estate partnerships is primarily determined using net asset values, which approximate fair value, as determined by an external fund manager based on quoted market prices, operating results, balance sheet stability, growth, and other business and market sector fundamentals.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

Deferred Compensation Plan Assets

The fair value of Level 3 deferred compensation plan assets is based on original investments into a guaranteed fund, plus guaranteed, annuity contract-based interest. Significant unobservable inputs to the guaranteed rate include the fair value and average duration of the portfolio of investments underlying annuity contract, the contract value, and the annualized weighted-average yield to maturity of the benchmark index of the underlying investment portfolio.

Interest Rate Swap Assets and Liabilities

The fair value of interest rate swaps is primarily determined using techniques consistent with the income method. Under the income method, fair values are calculated based on present value of expected future cash flows using discount rates appropriate with risks involved.

Significant observable inputs to valuation models include interest rates, Treasury yields, volatilities, credit spreads, maturity, and recovery rates.

Investments Sold, Not Yet Purchased

The fair value of investments sold, not yet purchased is based on the nature of the underlying securities, which may include equity or fixed income securities, and whose valuation techniques are consistent with these security types as discussed above.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

The following tables summarize fair value measurements, by level, at March 31, 2026 and June 30, 2025, for all financial assets and liabilities measured at fair value on a recurring basis in the System's Consolidated Financial Statements.

	Level 1	Level 2	Level 3	Total
March 31, 2026				
Cash equivalents	\$ 21,735	\$ 152,772	\$ -	\$ 174,507
Short-term investments	28,230	5,482	-	33,712
Pooled short-term investment fund	1,577,337	-	-	1,577,337
U.S. government, state, municipal and agency obligations	-	5,039,692	-	5,039,692
Corporate and foreign fixed income securities	-	974,022	1,342	975,364
Asset-backed securities	-	1,203,451	222,106	1,425,557
Equity securities	7,027,040	2,195	6,047	7,035,282
Alternative investments and other investments:				
Private equity	-	-	632,037	632,037
Other investments, including derivatives, net	327,940	51,743	2,291	381,974
Assets at net asset value:				
Equity securities				7,650
Private equity funds and real estate funds				4,409,208
Private credit and energy funds				1,020,213
Hedge funds				550,498
Cash and other investments not at fair value				<u>545,566</u>
Cash and investments				<u>\$ 23,808,597</u>
Deferred compensation plan assets, in other noncurrent assets	\$ 78	\$ -	\$ 38	\$ 116
Investments sold, not yet purchased, in other noncurrent liabilities	39	-	-	39
Interest rate swaps, included in other noncurrent liabilities ¹	-	-	-	-

¹See Derivative Instruments note.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

	Level 1	Level 2	Level 3	Total
June 30, 2025				
Cash equivalents	\$ 30,498	\$ 1,855	\$ -	\$ 32,353
Short-term investments	31,239	5,355	-	36,594
Pooled short-term investment fund	940,858	-	-	940,858
U.S. government, state, municipal and agency obligations	-	1,943,706	-	1,943,706
Corporate and foreign fixed income securities	-	919,379	1,737	921,116
Asset-backed securities	-	970,939	216,600	1,187,539
Equity securities	7,195,135	14,778	5,932	7,215,845
Alternative investments and other investments:				
Private equity	-	-	603,986	603,986
Other investments, including derivatives, net	337,584	5,998	2,246	345,828
Assets at net asset value:				
Equity securities				10,804
Private equity funds and real estate funds				4,401,777
Private credit and energy funds				1,175,108
Hedge funds				523,261
Other investments				1,370
Cash and other investments not at fair value				<u>694,736</u>
Cash and investments				<u>\$ 20,034,881</u>
Deferred compensation plan assets, in other noncurrent assets	\$ 713,136	\$ -	\$ 33,249	\$ 746,385
Investments sold, not yet purchased, in other noncurrent liabilities	20	492	-	512
Interest rate swaps, included in other noncurrent liabilities	-	23,057	-	23,057

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

For the three months ended March 31, 2026 and 2025, the changes in the fair value of the assets and liabilities measured using significant unobservable inputs (Level 3) consisted of the following:

	Corporate and Foreign Fixed Income Securities	Asset- Backed Securities	Equity Securities	Private Equity	Other Investments	Deferred Compensation Plan Assets
The three months ended						
March 31, 2026						
Beginning balance	\$ 1,682	\$ 223,361	\$ 6,011	\$ 618,839	\$ 2,282	\$ 33,337
Realized and unrealized gains (losses):						
Included in nonoperating gains (losses)	61	(1,960)	36	(11,073)	15	-
Included in changes in net assets	-	-	-	-	(9)	-
Purchases	-	21,074	-	20,081	18	6,460
Issuances	-	-	-	279	-	-
Sales	(401)	(20,240)	-	(3,434)	(15)	(25,940)
Transfers into Level 3	-	-	-	7,451	-	200
Transfers out of Level 3	-	(129)	-	(106)	-	(14,019)
Ending balance	<u>\$ 1,342</u>	<u>\$ 222,106</u>	<u>\$ 6,047</u>	<u>\$ 632,037</u>	<u>\$ 2,291</u>	<u>\$ 38</u>
The amount of total gains or losses for the period included in nonoperating gains (losses) attributable to the changes in unrealized gains or losses relating to assets still held at March 31, 2026.						
	<u>\$ 74</u>	<u>\$ (2,012)</u>	<u>\$ 41</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

	Corporate and Foreign Fixed Income Securities	Asset- Backed Securities	Equity Securities	Private Equity	Other Investments	Deferred Compensation Plan Assets
The three months ended						
March 31, 2025						
Beginning balance	\$ 1,780	\$ 222,961	\$ 5,847	\$ 761,391	\$ 2,249	\$ 38,284
Realized and unrealized gains (losses):						
Included in nonoperating gains (losses)	(25)	(268)	27	(12,320)	(3)	-
Included in changes in net assets	-	-	-	-	(2)	-
Purchases	-	15,832	-	1,633	16	575
Issuances	-	-	-	14	-	-
Sales	-	(22,034)	-	(1,940)	(15)	(4,207)
Transfers into Level 3	-	-	-	-	-	636
Transfers out of Level 3	-	(855)	-	-	-	(405)
Ending balance	<u>\$ 1,755</u>	<u>\$ 215,636</u>	<u>\$ 5,874</u>	<u>\$ 748,778</u>	<u>\$ 2,245</u>	<u>\$ 34,883</u>
The amount of total gains or losses for the period included in nonoperating gains (losses) attributable to the changes in unrealized gains or losses relating to assets still held at March 31, 2025.						
	<u>\$ (25)</u>	<u>\$ (269)</u>	<u>\$ 1</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

For the nine months ended March 31, 2026 and 2025 the changes in the fair value of the assets and liabilities measured using significant unobservable inputs (Level 3) consisted of the following:

	Corporate and Foreign Fixed Income Securities	Asset- Backed Securities	Equity Securities	Private Equity	Other Investments	Deferred Compensation Plan Assets
The nine months ended						
March 31, 2026						
Beginning balance	\$ 1,737	\$ 216,600	\$ 5,932	\$ 603,986	\$ 2,246	\$ 33,249
Realized and unrealized gains (losses):						
Included in nonoperating gains (losses)	6	(2,499)	116	(16,656)	46	-
Included in changes in net assets	-	-	-	-	(3)	-
Purchases	-	86,010	1	56,545	48	10,828
Issuances	-	-	-	1,160	-	-
Sales	(401)	(78,005)	(10)	(41,924)	(46)	(26,670)
Transfers into Level 3	-	-	8	39,988	-	6,643
Transfers out of Level 3	-	-	-	(11,062)	-	(24,012)
Ending balance	<u>\$ 1,342</u>	<u>\$ 222,106</u>	<u>\$ 6,047</u>	<u>\$ 632,037</u>	<u>\$ 2,291</u>	<u>\$ 38</u>

The amount of total gains or losses for the period included in nonoperating gains (losses) attributable to the changes in unrealized gains or losses relating to assets still held at March 31, 2026.

<u>\$ 15</u>	<u>\$ (2,820)</u>	<u>\$ 119</u>	<u>\$ 538</u>	<u>\$ 1</u>	<u>\$ -</u>
--------------	-------------------	---------------	---------------	-------------	-------------

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

7. Fair Value Measurements (continued)

	Corporate and Foreign Fixed Income Securities	Asset- Backed Securities	Equity Securities	Private Equity	Other Investments	Deferred Compensation Plan Assets
The nine months ended						
March 31, 2025						
Beginning balance	\$ 1,714	\$ 219,942	\$ 9,321	\$ 368,083	\$ 2,203	\$ 42,638
Realized and unrealized gains (losses):						
Included in nonoperating gains (losses)	41	2,076	54	(12,046)	41	-
Purchases	-	86,448	6,853	15,690	47	1,466
Issuances	-	-	-	2,523	-	-
Sales	-	(90,690)	(10,403)	(3,705)	(46)	(6,414)
Transfers into Level 3	-	-	49	378,233	-	1,381
Transfers out of Level 3	-	(2,140)	-	-	-	(4,188)
Ending balance	<u>\$ 1,755</u>	<u>\$ 215,636</u>	<u>\$ 5,874</u>	<u>\$ 748,778</u>	<u>\$ 2,245</u>	<u>\$ 34,883</u>

The amount of total gains or losses for the period included in nonoperating gains (losses) attributable to the changes in unrealized gains or losses relating to assets still held at March 31, 2025.

\$ 50	\$ 930	\$ (4,634)	\$ -	\$ 1	\$ -
-------	--------	------------	------	------	------

The basis for recognizing and valuing transfers into or out of Level 3, in the Level 3 rollforward, is as of the beginning of the period in which the transfers occur.

8. Debt

Ascension completed various debt-related activities in November and December 2025 resulting in the issuance of taxable and tax-exempt bonds, refunding of certain outstanding tax-exempt bonds, amendment and restatement of Ascension's Master Trust Indenture (MTI), and defeasance and discharge of existing subordinate debt obligations, as further noted below.

In November 2025, Ascension issued \$2,095,000 of taxable bonds. The proceeds of these bonds were used for the defeasance of outstanding tax-exempt subordinate bonds, to pay costs of issuance, and for corporate purposes of Ascension.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Debt (continued)

In December 2025, Ascension issued \$2,451,700 of tax-exempt bonds through issuing authorities in Indiana, Tennessee, and Texas. The proceeds of these bonds, including original issue premium of \$181,982, were used to finance, refinance, or reimburse Ascension for all or a portion of certain capital projects and refund certain tax-exempt revenue bonds issued previously for the benefit of Ascension and certain affiliates. The refunded bonds include the Indiana Health Facility Financing Authority Revenue Bonds Series 2001A-1 and 2003E-6, Indiana Finance Authority Revenue Bonds Series 2008E-4, E-5, E-7, and E-8, and the Health and Educational Facility Authority of the State of Missouri Revenue Bonds Series 2003 C-2 and C-3, and totaled \$407,610. At March 31, 2026, approximately \$704,600 of the tax-exempt bond proceeds are held by the bond trustee and reported on the Consolidated Balance Sheet within assets limited as to use until reimbursement of eligible capital project spending occurs.

In December 2025, the Amended and Restated MTI became effective, replacing the Original MTI, dated November 1, 1999 (Original MTI) and its amendments in its entirety. All existing MTI obligations were carried forward as obligations subject to the Amended and Restated MTI.

A Subordinate Credit Group was previously established under Ascension's Subordinate MTI. During the nine months ending March 31, 2026, the System fully discharged and terminated the Subordinate MTI through repayment and defeasance of its outstanding subordinate debt, which was \$39,640 as of June 30, 2025.

As provided by both the Amended and Restated MTI and Original MTI, certain members of the System comprise the Ascension Health Alliance Credit Group (Senior Credit Group). Each Senior Credit Group member may be identified as either a senior obligated group member, a senior designated affiliate, or a senior limited designated affiliate. Senior obligated group members are jointly and severally liable under the Amended and Restated MTI to make all payments required with respect to obligations under the Amended and Restated MTI.

Senior designated affiliates and senior limited designated affiliates are not obligated to make debt service payments on the obligations under the Amended and Restated MTI. The System may cause each senior designated affiliate to transfer amounts, as necessary, to enable the obligated group to comply with the terms of the Amended and Restated MTI, including payment of the outstanding obligations.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Debt (continued)

Additionally, senior limited designated affiliates have an independent limited designated affiliate agreement and promissory note with the System with stipulated repayment terms and conditions, each subject to the governing law of the senior limited designated affiliate's state of incorporation.

Pursuant to the Amended and Restated MTI, senior obligated group members, which are operating entities, have pledged and assigned to the Master Trustee a security interest in all of their rights, title, and interest in their pledged revenues and proceeds thereof.

The unsecured variable rate demand bonds of the Senior Credit Group, while subject to long-term amortization periods, may be put to the System at the option of the bondholders in connection with certain remarketing dates. To the extent bondholders may, under the terms of the debt, put their bonds within twelve months after March 31, 2026, the principal amount of such bonds has been classified as a current liability in the Consolidated Balance Sheets. Management believes the likelihood of a material amount of bonds being put to the System to be remote.

In December 2025, Ascension increased its commercial paper program authorization from \$1,000,000 to \$2,000,000. During the nine months ended March 31, 2026, Ascension both issued and repaid commercial paper resulting in net repayments of \$319,107 and an outstanding balance of \$49,857 at March 31, 2026, included in Short-term debt obligations on the Consolidated Balance Sheet.

As of March 31, 2026, the Senior Credit Group has a line of credit totaling \$1,000,000, committed through November 18, 2027. The Senior Credit Group has an additional \$500,000 line of credit committed through August 12, 2026. If drawn upon, funds from these lines of credit can be used for general corporate purposes. No amounts were outstanding under these lines of credit at March 31, 2026 or June 30, 2025.

As of March 31, 2026 and June 30, 2025, the Senior Credit Group has a \$100,000 revolving line of credit related to its letters of credit program for which a bank commitment of \$100,000 extends to November 8, 2027. The revolving line of credit may be accessed solely in the form of letters of credit issued by the bank for, or at the request of, Ascension.

Of this \$100,000 revolving line of credit, letters of credit of approximately \$67,965 were issued as of March 31, 2026. There were no borrowings outstanding under this program as of March 31, 2026 or June 30, 2025.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

8. Debt (continued)

Debt at March 31, 2026 and June 30, 2025 is comprised of the following:

	March 31, 2026	June 30, 2025
Short-term debt:		
Short-term debt obligations	\$ 49,857	\$ 368,963
Long-term debt:		
Tax-exempt hospital revenue bonds - secured under Ascension's MTI	\$ 5,137,600	\$ 2,391,605
Tax-exempt hospital revenue bonds - unsecured under Ascension's Subordinate MTI	-	39,640
Taxable bonds - secured under Ascension's MTI	4,321,850	3,042,600
Total hospital revenue bonds - all Master Trust Indentures	9,459,450	5,473,845
Other	87,667	71,014
	9,547,117	5,544,859
Unamortized premium, net	321,917	170,864
Less debt issuance cost, net	(45,823)	(26,123)
Less current portion	(94,025)	(102,018)
Less long-term debt subject to short-term remarketing arrangements	(700,000)	(343,685)
Long-term debt	\$ 9,029,186	\$ 5,243,897

9. Derivative Instruments

As provided for in Ascension's MTI, the System may use interest rate swap agreements to manage interest rate risk associated with its outstanding debt. Interest rate swaps have historically been used to effectively convert interest rates on variable rate bonds to fixed rates or on fixed rate bonds to variable rates. Ascension utilized interest rate swaps during the fiscal year ended June 30, 2025 and through their termination date of November 25, 2025.

The System did not designate its outstanding interest rate swaps as hedges, and as such, all gains and losses have been recognized as nonoperating gains (losses).

At June 30, 2025, the notional value of outstanding interest rate swaps was \$401,475, with maturity dates which ranged from August 2029 through November 2036. The fair value of these swaps, all of which were in a liability position at June 30, 2025, was \$23,057, included in Other noncurrent liabilities in the Consolidated Balance Sheet.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

10. Leases

The System is a party to real estate and equipment (medical and IT) leases as a lessee and real estate leases as a lessor. Rental escalation clauses or renewal options are factored into the determination of lease payments when appropriate. To determine the present value of lease payments, the System utilizes its incremental borrowing rate at lease commencement when an implicit rate is not available for operating leases. In addition, the System does not separate lease and non-lease components.

The following table provides the total lease cost included in Other operating expenses in the Consolidated Statement of Operations and Changes in Net Assets, excluding interest on lease liabilities, which is included in Interest expense in the Consolidated Statement of Operations and Changes in Net Assets:

	The three months ended		The nine months ended	
	March 31,		March 31,	
	2026	2025	2026	2025
Operating lease cost	\$ 64,276	\$ 65,703	\$ 181,312	\$ 214,225
Finance lease cost:				
Interest on lease liabilities	680	692	2,069	2,081
Amortization of right-of-use-asset	710	710	2,129	2,129
Variable lease cost	15,082	17,452	42,495	51,496
Total lease cost	\$ 80,748	\$ 84,557	\$ 228,005	\$ 269,931

The weighted average remaining lease terms and the weighted average discount rates at March 31, 2026 and 2025 were as follows:

	March 31, 2026		March 31, 2025	
	Operating Leases	Finance Leases	Operating Leases	Finance Leases
Weighted-average remaining lease term	7.8 years	23.8 years	8.8 years	24.8 years
Weighted-average discount rate	4.0%	3.3%	3.5%	3.3%

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

10. Leases (continued)

The following table provides the cash paid for amounts included in the measurement of lease obligations:

	The three months ended March 31,		The nine months ended March 31,	
	2026	2025	2026	2025
Operating leases	\$ 58,939	\$ 63,378	\$ 175,361	\$ 208,971
Finance leases	1,022	1,004	3,031	2,978
Total cash paid	<u>\$ 59,961</u>	<u>\$ 64,382</u>	<u>\$ 178,392</u>	<u>\$ 211,949</u>

The following table reconciles undiscounted future operating and finance lease obligations for each of the next five years and thereafter, as of March 31, 2026, to Lease obligations recorded on the Consolidated Balance Sheet at March 31, 2026.

Twelve Months Ending March 31,	Operating Leases	Finance Leases	Total
2027	\$ 203,960	\$ 4,108	\$ 208,068
2028	169,006	4,182	173,188
2029	132,439	4,245	136,684
2030	103,405	4,265	107,670
2031	82,296	4,343	86,639
Thereafter	275,894	95,118	371,012
Total future undiscounted lease obligations	967,000	116,261	1,083,261
Less: amount of lease payments representing interest	(47,267)	(38,447)	(85,714)
Present value of future lease obligations	919,733	77,814	997,547
Less: current portion of lease obligations	(190,685)	(1,421)	(192,106)
Long-term lease obligations	<u>\$ 729,048</u>	<u>\$ 76,393</u>	<u>\$ 805,441</u>

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

10. Leases (continued)

For leases where the System is a lessor, future minimum noncancelable receipts on operating leases for each of the next five years and thereafter, as of March 31, 2026, are as follows:

Twelve Months Ending March 31:	Operating Leases
2027	\$ 52,803
2028	44,047
2029	38,115
2030	33,901
2031	27,296
Thereafter	291,065
Total	\$ 487,227

For the three months ended March 31, 2026 and 2025, lease income was approximately \$15,000 and \$16,000, respectively. For the nine months ended March 31, 2026 and 2025, lease income was approximately \$45,000 and \$51,000, respectively.

11. Retirement Plans

Defined-Benefit Plans

Certain System entities participate in noncontributory, defined-benefit pension plans (the System Plans), which include traditional and cash balance plans. Benefits are based on each participant's years of service and compensation. Primarily all of the System Plans' assets are invested in the Master Pension Trust (the Trust).

Contributions to the System Plans are based on actuarially determined amounts sufficient to meet the benefits to be paid to participants. As of December 31, 2019, all System Plans were frozen.

The assets of the System Plans are available to pay the benefits of eligible employees and retirees of all participating entities. In the event certain entities participating in the System Plans are unable to fulfill their financial obligations under the System Plans, other participating entities are obligated to do so.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

11. Retirement Plans (continued)

The following table provides the components of net periodic benefit gain for the System Plans included in Other nonoperating gains (losses) in the Consolidated Statements of Operations and Changes in Net Assets.

	The three months ended March 31,		The nine months ended March 31,	
	2026	2025	2026	2025
Components of net periodic benefit gain:				
Expected return on plan assets	\$ 143,759	\$ 147,160	\$ 431,276	\$ 441,481
Interest cost	(98,672)	(102,487)	(296,016)	(307,460)
Amortization of actuarial loss	(26,995)	(24,638)	(80,986)	(73,914)
Amortization of prior service credit	9	9	28	28
Net periodic benefit gain	<u>\$ 18,101</u>	<u>\$ 20,044</u>	<u>\$ 54,302</u>	<u>\$ 60,135</u>

12. Self Insurance Programs

Ascension entities are self-insured for professional and general liability claims on a claims-made basis, as well as workers compensation claims on an occurrence basis, through grantor trusts and Ascension Health Insurance, Ltd. (AHIL), a captive insurance company and direct subsidiary of Ascension Risk Services. The grantor trusts provide funding for claims within the self-insured retentions. Actuarially determined amounts are contributed to the trust funds to provide for the estimated cost of claims.

The associated loss reserves recorded for estimated self-insured professional, general liability, and workers' compensation claims include estimates of the ultimate costs for both reported claims and claims incurred but not reported.

Employed physicians and certain entities in the states of Indiana and Kansas are provided coverage by ProAssurance Corporation on a fronted basis and are reinsured through AHIL. These entities and physicians are provided professional liability coverage with limits in compliance with participation in the state-specific Patient Compensation Fund programs.

Sunflower Assurance, Ltd., a captive insurance company and wholly owned subsidiary of Ascension Risk Services, offers physician professional liability coverage through insurance or reinsurance arrangements to non-employed physicians practicing at various facilities of the System.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

13. Related Parties

The System has an agreement with a related party for clinical engineering services, under a committed contract through 2032. Expenses for clinical engineering services for the three months ended March 31, 2026 and 2025 were approximately \$77,000 and \$82,000, respectively. Expenses for clinical engineering services for the nine months ended March 31, 2026 and 2025 were approximately \$232,000 and \$265,000, respectively.

The System has certain agreements with HFHS (see Organizational Changes note) to provide revenue cycle, information technology, facilities management and finance services. Revenue recognized for these services was approximately \$66,000 and \$42,000 for the three months ended March 31, 2026 and 2025, respectively. Revenue recognized for these services was approximately \$202,000 and \$82,000 for the nine months ended March 31, 2026 and 2025, respectively.

14. Commitments and Contingencies

Ascension, like other healthcare organizations, periodically undergoes investigations or audits by federal, state and local agencies involving compliance with a variety of laws and regulations arising in the ordinary course of business. These investigations generally seek to determine compliance with, among other things, laws and regulations relating to Medicare and Medicaid reimbursement, including billing practices for certain services. To support compliance with these laws and regulations, Ascension maintains a compliance program designed to prevent, proactively detect, and correct potential violations of laws and regulations.

The System is also periodically involved in litigation arising in the ordinary course of business. While no assurance can be given concerning the outcome of any current investigation or litigation and the related impact to consolidated financial statements, management believes that adequate reserves have been established, where estimates of liability have been or can be reached, and that the outcome of any current investigation and litigation is expected to be resolved without a material adverse effect on the financial position or liquidity of the system.

The System anticipates making payments under various committed contracts as follows: approximately \$3,200,000 for information technology and other purchased services over the next 1 - 6 years and approximately \$2,800,000 for supplies over the next 2 years. Additionally, the System has a committed contract through 2031 for revenue cycle services, for which expenses of approximately \$500,000 were incurred for the nine months ended March 31, 2026.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

14. Commitments and Contingencies (continued)

The System also has outstanding guarantees of third party financing arrangements for certain affiliates at March 31, 2026 of approximately \$43,000 for up to 14 years. Payments under these commitments may not be required, depending on the performance of the affiliates.

15. Functional Expenses

Ascension provides healthcare services, including inpatient, outpatient, ambulatory, long-term care and community-based services. Management support services include information technology, finance and accounting, revenue cycle, public relations, human resources, legal, supply chain, risk management, compliance, administration and other related functions. Expenses are classified as healthcare services and management support services based on the functional department for which they are incurred. Departmental expenses may include various allocations of costs based on direct assignment, expenses or other methods.

Expenses by functional classification for the three months ended March 31, 2026 consist of the following:

	Healthcare services	Management support services	Total
Salaries, wages, and employee benefits	\$ 2,439,172	\$ 265,467	\$ 2,704,639
Purchased services and professional fees	807,704	297,626	1,105,330
Supplies	833,057	242	833,299
Other	1,276,050	126,626	1,402,676
Total operating expenses	\$ 5,355,983	\$ 689,961	\$ 6,045,944

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

15. Functional Expenses (continued)

Expenses by functional classification for the three months ended March 31, 2025 consist of the following:

	Healthcare services	Management support services	Total
Salaries, wages, and employee benefits	\$ 2,513,104	\$ 277,215	\$ 2,790,319
Purchased services and professional fees	864,511	334,304	1,198,815
Supplies	823,909	253	824,162
Other	1,174,916	126,405	1,301,321
Total operating expenses	\$ 5,376,440	\$ 738,177	\$ 6,114,617

Expenses by functional classification for the nine months ended March 31, 2026 consist of the following:

	Healthcare services	Management support services	Total
Salaries, wages, and employee benefits	\$ 7,362,974	\$ 898,981	\$ 8,261,955
Purchased services and professional fees	2,422,827	919,069	3,341,896
Supplies	2,507,256	759	2,508,015
Other	3,889,615	340,678	4,230,293
Total operating expenses	\$ 16,182,672	\$ 2,159,487	\$ 18,342,159

Expenses by functional classification for the nine months ended March 31, 2025 consist of the following:

	Healthcare services	Management support services	Total
Salaries, wages, and employee benefits	\$ 8,357,140	\$ 810,180	\$ 9,167,320
Purchased services and professional fees	2,764,910	1,040,155	3,805,065
Supplies	2,726,987	884	2,727,871
Other	3,833,081	426,617	4,259,698
Total operating expenses	\$ 17,682,118	\$ 2,277,836	\$ 19,959,954

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

16. Community Benefit

The System's community benefit is prepared in accordance with Internal Revenue Service Form 990, Schedule H and the Catholic Health Association of the United States' (CHA) publication, *A Guide for Planning and Reporting Community Benefit*. Community benefit costs included below relate to System entities, including, but not limited to, licensed hospital facilities. For entities sold during the nine months ended March 31, 2026 and 2025, Care of persons living in poverty and other community benefit programs included in the following table reflect the costs of community benefit through the entities' sale dates (See Organizational Changes note). Community benefit for the nine months ended March 31, 2026 and 2025, respectively, consists of the following:

	The nine months ended March 31,	
	2026	2025
Traditional charity care provided	\$ 355,932	\$ 407,501
Unpaid cost of public programs for persons living in poverty	276,777	487,466
Programs for persons living in poverty, other persons who are vulnerable and the broader community:		
Community health improvement services	51,777	42,135
Health professions education	137,189	200,254
Subsidized health services	38,280	38,427
Research	1,535	1,333
Financial contributions	19,633	19,787
Community building activities	886	996
Community benefit operations	799	3,492
Cost of programs for persons living in poverty, other persons who are vulnerable and the broader community	250,099	306,424
Care of persons living in poverty and other community benefit programs	882,808	1,201,391
Unpaid costs of Medicare	1,258,220	1,440,442
Community Benefit	\$ 2,141,028	\$ 2,641,833

Traditional charity care provided includes the cost of services provided to persons who cannot afford healthcare because of inadequate resources, including those who are insured or underinsured.

Ascension

Notes to Consolidated Financial Statements (unaudited) (continued) (Dollars in Thousands)

16. Community Benefit (continued)

Unpaid cost of public programs for persons living in poverty, excluding Medicare, represents the unpaid cost of services provided to persons covered by public programs for persons living in poverty and other vulnerable persons.

Community health improvement services are carried out to improve community health and include community health education, outreach and prevention services. These services do not generate patient bills, although they may involve a nominal fee.

Health professions education includes educational programs for physicians, interns and residents, medical students, nurses and nursing students, pastoral care trainees, and other health professionals when that education is necessary to retain state licensure or certification by a board in the individual's health profession specialty.

Subsidized health services are clinical services provided by the System to meet an identified community need, despite a financial loss after removing the effects of bad debt, financial assistance, Medicaid and other means-tested government programs.

Research includes unreimbursed clinical and community health research and studies on health care delivery, which is generalizable and shared with the public.

Financial contributions include cash contributions or grants and the cost of in-kind contributions that support financial assistance, health professions education and other community benefit activities. In-kind contributions include the cost of associate time and other nonmonetary resources donated for community benefit.

Community building activities seek to address the root causes of health problems, such as discrimination, poverty, homelessness and environmental hazards. They include programs such as housing, economic development and environmental improvement.

Community benefit operations include the cost of assigned staff, consultants and activities of the community benefit team, such as community assessments and program evaluations and community benefit planning.

Supplementary Information

Ascension

Credit Group Financial Statements
 Balance Sheet (unaudited)
 (Dollars in Thousands)

	March 31,
	2026
Assets	
Current assets:	
Cash and cash equivalents	\$ 310,539
Short-term investments	36,264
Accounts receivable	2,763,526
Inventories	433,845
Estimated third-party payor settlements	528,975
Due from affiliates (See Note 2)	213,011
Other	1,015,381
Total current assets	<u>5,301,541</u>
Long-term investments	18,925,964
Property and equipment, net	7,925,690
Other assets:	
Right-of-use assets - leases	789,629
Investment in unconsolidated entities	2,508,302
Intangible assets, net	1,150,910
Due from affiliates (See Note 2)	541,718
Other	1,255,398
Total other assets	<u>6,245,957</u>
Total assets	<u><u>\$ 38,399,152</u></u>

Continued on next page.

Ascension

Credit Group Financial Statements Balance Sheet (unaudited) (Dollars in Thousands)

		March 31, 2026
Liabilities and net assets		
Current liabilities:		
Current portion of long-term debt	\$	95,224
Long-term debt subject to short-term remarketing arrangements ¹		700,000
Short-term debt obligations		49,857
Current portion of lease obligations		190,508
Accounts payable and accrued liabilities		2,856,097
Estimated third-party payor settlements		274,766
Due to affiliates (See Note 2)		46,347
Other		435,611
Total current liabilities		4,648,410
Noncurrent liabilities:		
Long-term debt		9,009,599
Lease obligations, less current portion		635,472
Pension and other postretirement liabilities		390,806
Other		1,275,164
Total noncurrent liabilities		11,311,041
Total liabilities		15,959,451
Net assets:		
Without donor restrictions:		
Controlling interest		21,412,873
Noncontrolling interests		405,521
Total net assets without donor restrictions		21,818,394
Net assets with donor restrictions		621,307
Total net assets		22,439,701
Total liabilities and net assets	\$	38,399,152

¹ Consists of variable rate demand bonds with put options that may be exercised at the option of the bondholders, with stated repayment installments through 2065. In the event that bonds are not remarketed upon the exercise of put options for the variable bonds, management would utilize other sources to access the necessary liquidity. Potential sources include a drawdown on the System's lines of credit, issuing commercial paper, and liquidating investments.

Ascension

Credit Group Financial Statements Statement of Operations and Changes in Net Assets (unaudited) (Dollars in Thousands)

	The nine months ended March 31, 2026
Operating revenue:	
Net patient service revenue	\$ 14,594,574
Other revenue <i>(See Note 2)</i>	1,957,517
Total operating revenue	16,552,091
Operating expenses <i>(See Note 2)</i> :	
Salaries and wages	6,135,650
Employee benefits	1,239,256
Purchased services	2,001,608
Professional fees	979,913
Supplies	2,322,788
Insurance	101,898
Interest	193,257
Provider tax	715,416
Depreciation and amortization	683,799
Other	2,017,688
Total operating expenses	16,391,273
Income (loss) from recurring operations	160,818
Impairment and nonrecurring gains (losses), net	(38,930)
Income (loss) from operations	121,888
Nonoperating gains (losses):	
Investment return, net	832,785
Other	7,114
Total nonoperating gains (losses), net	839,899
Excess (deficit) of revenues and gains over expenses and losses	961,787
Less noncontrolling interests	17,411
Excess (deficit) of revenues and gains over expenses and losses attributable to controlling interest	944,376

Continued on next page.

Ascension

Credit Group Financial Statements Statement of Operations and Changes in Net Assets (unaudited) (Dollars in Thousands)

	The nine months ended March 31, 2026
Net assets without donor restrictions, controlling interest:	
Excess (deficit) of revenues and gains over expenses and losses	\$ 944,376
Transfers (to) from affiliates, net <i>(See Note 2)</i>	(942,765)
Net assets released from restrictions for property acquisitions	12,444
Change in pension liability	80,958
Change in unconsolidated entities' net assets	9,349
Other	4,917
Increase (decrease) in net assets without donor restrictions, controlling interest	109,279
Net assets without donor restrictions, noncontrolling interest:	
Excess (deficit) of revenues and gains over expenses and losses	17,411
Net contributions (distributions) of capital	(98,041)
Change in membership interest	1,320
Other	(366)
Increase (decrease) in net assets without donor restrictions, noncontrolling interest	(79,676)
Net assets with donor restrictions:	
Contributions and grants	67,783
Investment return	33,771
Net assets released from restrictions	(52,738)
Divestitures	(10,565)
Other	(9,210)
Increase (decrease) in net assets with donor restrictions	29,041
Increase (decrease) in net assets	58,644
Net assets, beginning of period	22,381,057
Net assets, end of period	\$ 22,439,701

Ascension
Notes to Credit Group Financial Statements (unaudited)
(Dollars in Thousands)

1. Credit Group Financial Statements

Ascension's Credit Group Financial Statements (CGFS), presented above as of and for the nine months ended March 31, 2026, were prepared in accordance with Section 3.10(b)(2)(c) of the Amended and Restated Master Trust Indenture (MTI), which provides that the CGFS (1) shall include all Material Credit Group Members, which represent obligated group members and designated affiliates whose total net assets were equal to or greater than 80% of the consolidated net assets of the Credit Group; (2) at the option of Ascension, as Group Representative, may include one or more Immaterial Affiliates, which are entities whose total net assets were less than 20% of the consolidated net assets of the Credit Group as shown on the CGFS; (3) at the option of Ascension, as Credit Group Representative, may exclude one or more Credit Group Members that are not Material Credit Group Members, as defined above; and (4) shall exclude all entities that are neither Credit Group Members nor Immaterial Affiliates. Consistent with these terms, the CGFS as of and for the nine months ended March 31, 2026 include the results of all Material Credit Group Members and certain Immaterial Affiliates, and exclude the results of certain entities which are not Material Credit Group members as well as entities that are not Credit Group Members, such as Ascension risk entities which oversee Ascension's self-insurance programs. Ascension's CGFS are not representative of the consolidated financial position or results of Ascension.

2. Affiliate Transactions

Amounts due to and from affiliates as presented in the Balance Sheet of the CGFS represent intercompany transactions between 1) Material Credit Group Members and Immaterial Affiliates (CGFS Entities) and 2) other entities that are included within the Ascension Consolidated Financial Statements whose results have been excluded from the CGFS (Non CGFS Entities), in accordance with Section 3.10(b)(2)(c) of the MTI. These transactions are primarily related to centralized cash and debt functions within Ascension. Current Due from and to affiliates on the CGFS Balance Sheet and Transfers (to) from affiliates, net in the CGFS Statement of Operations and Changes in Net Assets primarily relate to payments made by or received from CGFS Entities on behalf of Non CGFS Entities, as well as transfers of certain restricted assets to Non CGFS Entities. Non-current Due from affiliates primarily represents the Non CGFS Entities' portion of Ascension's long-term debt, based on internal centralized debt agreements.

Ascension
Notes to Credit Group Financial Statements (unaudited) (continued)
(Dollars in Thousands)

2. Affiliate Transactions (continued)

These transactions are eliminated in consolidation within the Ascension Consolidated Financial Statements, but separately presented within the CGFS.

Revenue and expense activities, not transacted at arms length, between CGFS Entities and Non CGFS Entities were both approximately \$316,000 for the nine months ended March 31, 2026. These transactions include services provided between CGFS Entities and Non CGFS Entities, including, but not limited to, shared service functions, participation in employee and dependent health insurance programs, participation in other risk management programs, participation in Ascension's centralized debt management program and other insurance services, and are included in Other revenue and various expense categories within the Statement of Operations of the CGFS.